Richard Horton on the Oxford vaccine phase 3 trial
The Lancet in conversation with - Un pódcast de The Lancet Group - Viernes
Categorías:
Editor-in-chief of The Lancet, Richard Horton, discusses the results of the Oxford vaccine's phase 3 trial.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
